CHRS — Coherus Oncology Income Statement
0.000.00%
Last trade - 00:00- $191.78m
- $4.11m
- $266.96m
- 73
- 42
- 70
- 67
Annual income statement for Coherus Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 476 | 327 | 211 | 257 | 267 |
| Cost of Revenue | |||||
| Gross Profit | 438 | 269 | 141 | 98.3 | 149 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 320 | 590 | 474 | 460 | 215 |
| Operating Profit | 156 | -264 | -263 | -203 | 52.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 136 | -287 | -292 | -238 | 28.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 132 | -287 | -292 | -238 | 28.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 132 | -287 | -292 | -238 | 28.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 136 | -287 | -292 | -238 | 28.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.62 | -3.81 | -3.68 | -2.46 | -1.06 |